The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists

Carcinogenesis

Volumn 33, Issue 7, 2012, Pages 1360-1367

  Sahu, Ravi P ^a   Turner, Matthew J ^a   Dasilva, Sonia C ^a   Rashid, Badri M ^a   Ocana, Jesus A ^a   Perkins, Susan M ^a   Konger, Raymond L ^a   Touloukian, Christopher E ^a   Kaplan, Mark H ^a   Travers, Jeffrey B ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; INTERLEUKIN 10; THROMBOCYTE ACTIVATING FACTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER GROWTH; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; ENVIRONMENTAL STRESS; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR IMMUNITY; ULTRAVIOLET B RADIATION; WILD TYPE;

ANIMALS; MELANOMA, EXPERIMENTAL; MICE; PLATELET ACTIVATING FACTOR; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; ULTRAVIOLET RAYS;

EID: 84865191706     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs152     Document Type: Article

References (51)

1. Miller,A.J. et al. (2004) Melanoma. N. Engl. J. Med., 355, 51-65.
2. Rigel,D.S. et al. (1996) The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol., 34, 839-847.
3. American Cancer Society. (2010) Cancer Facts & Figures. http:// www.cancer.org/downloads/STT/500809web.pdf.
4. Jilaveanu,L.B. et al. (2009) Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol., 27, 614-625.
5. Agarwala,S.S. (2010) Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res., 20, 1-10.
6. Kaehler,K.C. et al. (2010) Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur. J. Cancer, 46, 41-46.
7. Fang,L. et al. (2008) Immunotherapy for advanced melanoma. J. Invest. Dermatol., 128, 2596-2605.
8. Carroll,R.P. et al. (2003) Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am. J. Kidney Dis., 41, 676-683.
9. Halliday,G.M. (2005) Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat. Res., 571, 107-120.
10. Fernandez,A.A. et al. (2011) An experimental population study of nucleotide excision repair as a risk factor for UVB-induced melanoma. Photochem. Photobiol., 87, 335-341.
11. Peus,D. et al. (1998) H2O2 is an important mediator of UVB-induced EGFreceptor phosphorylation in cultured keratinocytes. J. Invest. Dermatol., 110, 966-971.
12. Konger,R.L. et al. (2008) Oxidized glycerophosphocholines as biologically active mediators for ultraviolet radiation-mediated effects. Prostaglandins Other Lipid Mediat., 87, 1-8.
13. Marathe,G.K. et al. (2005) Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J. Biol. Chem., 280, 35448-35457.
14. Ullrich,S.E. (2005) Mechanisms underlying UV-induced immune suppression. Mutat. Res., 571, 185-205.
15. Walterscheid,J.P. (2002) Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J. Exp. Med., 195, 171-179.
16. Zhang,Q. et al. (2008) UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system. J. Invest. Dermatol., 128, 1780-1787.
17. Yao,Y. et al. (2009) Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species. J. Immunol., 182, 2842-2848.
18. Blank,M.L. et al. (1990) Characterization of the enzymatic hydrolysis of acetate from alkylacetylglycerols in the de novo pathway of PAF biosynthesis. Biochem. Biophys. Acta, 1042, 153-158.
19. Ishii,S. et al. (2002) Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat., 68-69, 599-609.
20. Zhuang,Q. et al. (2000) Activation via multiple signaling pathways induces down-regulation of platelet-activating factor receptors on human B lymphocytes. J. Immunol., 165, 2423-2431.
21. Travers,J.B. et al. (1995) Identification of functional platelet-activating factor receptors on human keratinocytes. J. Invest. Dermatol., 105, 816-823.
22. Stafforini,D.M. et al. (2003) Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit. Rev. Clin. Lab. Sci., 40, 643-672.
23. Marques,S.A. et al. (2002) The platelet-activating factor receptor activates the ERK MAP kinase and induces proliferation of epidermal cells through an EGF receptor-dependent pathway. J. Pharmacol. Exp. Ther., 300, 1026-1035.
24. Melnikova,V.O. et al. (2006) Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response elementbinding protein and contributes to melanoma metastasis. J. Biol. Chem., 281, 2911-2922.
25. Heon,S.K. et al. (2006) Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation. Cancer Res., 66, 4681-4686.
26. Biancone,L. et al. (2003) Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin. Cancer Res., 9, 4214-4220.
27. de Oliveira,S.I. et al. (2010) Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. BMC Cancer, 10, 200.
28. Hart,P.H. et al. (2002) Mast cells, neuropeptides, histamine, and prostaglandins in UV-induced systemic immunosuppression. Methods, 28, 79-89.
29. Poon,T.S. et al. (2005) Sunlight-induced immunosuppression in humans is initially because of UVB, then UVA, followed by interactive effects. J. Invest. Dermatol., 125, 840-846.
30. Beissert,S. et al. (2009) Ultraviolet-induced immunosuppression: implications for photocarcinogenesis. Cancer Treat. Res., 146, 109-121.
31. Im,S.Y. et al. (1996) Augmentation of tumor metastasis by platelet-activating factor. Cancer Res., 56, 2662-2665.
32. Pei,Y. et al. (1998) Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J. Immunol., 161, 1954-1961.
33. Ishii,S. et al. (1998) Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med., 187, 1779-1788.
34. Bettelli,E. et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 441, 235-238.
35. Schwarz,T. (2008) 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. J. Photochem. Photobiol., 84, 10-18.
36. Sreevidya,C.S. et al. (2008) Inhibition of photocarcinogenesis by plateletactivating factor or serotonin receptor antagonists. Cancer Res., 68, 3978-3984.
37. Travers,J.B. et al. (2010) Ultraviolet B radiation of human skin generates platelet-activating factor receptor agonists. Photochem. Photobiol., 86, 949-954.
38. Travers,J.B. (1999) Oxidative stress can activate the epidermal plateletactivating factor receptor. J. Invest. Dermatol., 112, 279-283.
39. Darst,M. et al. (2004) Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line. J. Immunol., 172, 6330-6335.
40. Lehr,H.A. et al. (1997) Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J. Clin. Invest., 99, 2358-2364.
41. Muralikrishnan,G. et al. (2010) Effect of vitamin C on lipidperoxidation and antioxidant status in tamoxifen-treated breast cancer patients. Chemotherapy, 56, 298-302.
42. An,S.H. et al. (2011) Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells. BMB Rep., 44, 211-216.
43. Elmets,C.A. et al. (1983) Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J. Exp. Med., 158, 781-794.
44. Soontrapa,K. et al. (2011) Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc. Natl Acad. Sci. USA, 108, 6668-6673.
45. Maeda,A. et al. (2008) Phenotypic and functional characterization of ultraviolet radiation-induced regulatory T cells. J. Immunol., 180, 3065-3071.
46. Raimondi,G. et al. (2007) Naturally occurring regulatory T cells: recent insights in health and disease. Crit. Rev. Immunol., 27, 61-95.
47. Hori,S. et al. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057-1061.
48. Matsumura,Y. et al. (2006) A role for inflammatory mediators in the induction of immunoregulatory B cells. J. Immunol., 177, 4810-4817.
49. Klages,K. et al. (2010) Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res., 70, 7788-7799.
50. Steitz,J. et al. (2001) Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res., 61, 8643-8646.
51. Donawho,C.K. et al. (1992) Immunologic factors in melanoma. Clin. Dermatol., 10, 69-74.